Patent Oppositions in form specific drugs industry

Explore the competitive field of form specific drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in form specific drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the form specific drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the form specific drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Antibody-Containing PreparationCHUGAI SEIYAKU KABUSHIKI KAISHAAug 19, 2026KERNEBECK PATENTANWALTS
Nicotine Particles And CompositionsPHILIP MORRISAug 19, 2026JT INTERNATIONAL S.A.
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 19, 2026WITHERS & ROGERS
Antibody-Containing PreparationCHUGAI SEIYAKU KABUSHIKI KAISHAAug 18, 2026STRAWMAN
Multi-Layer Nicotine-Containing Pharmaceutical CompositionMODORAL BRANDSAug 18, 2026PHILIP MORRIS
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 17, 2026LUMARA BIO ONCOLOGICS
Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]UreaPFIZERAug 16, 2026ELKINGTON AND FIFE
Ribociclib TabletNOVARTISAug 12, 2026STADA ARZNEIMITTEL
Pharmaceutical CompositionMEXICHEM FLUOR DE CVAug 11, 2026HGF
Pharmaceutical Composition Comprising EnzalutamideSYNTHONAug 11, 2026IPSILON BELGIUM

To stay ahead in the competitive form specific drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the form specific drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Jan 17, 2024Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIM18
Jan 7, 2026Formulations Of EnzalutamideASTELLAS PHARMA14
Dec 11, 2019Rapid Dissolution Formulation Of A Cinacalcet HclAMGEN12
Nov 13, 2019Apixaban FormulationsPFIZER12
May 10, 2017Pharmaceutical Preparation Containing Oxycodone And NaloxoneMUNDIPHARMA11
May 10, 2017Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUE11
Dec 11, 2019Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor AgonistNOVARTIS11
Aug 20, 2025Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPE11
Oct 16, 2019Apixaban FormulationsBRISTOL MYERS SQUIBB IRELAND UNLIMITED10
Mar 2, 2022Modified Nucleoside, Nucleotide, And Nucleic Acid CompositionsMODERNA10